Literature DB >> 19592080

Toll-like receptor 7 and 9 defects in common variable immunodeficiency.

Joyce E Yu1, Adina K Knight, Lin Radigan, Thomas U Marron, Li Zhang, Silvia Sanchez-Ramón, Charlotte Cunningham-Rundles.   

Abstract

BACKGROUND: Common variable immunodeficiency (CVID) is characterized by hypogammaglobulinemia, reduced numbers of peripheral blood isotype-switched memory B cells, and loss of plasma cells.
OBJECTIVE: Because Toll-like receptor (TLR) activation of B cells can initiate and potentially sustain normal B cell functions, we examined functional outcomes of TLR7 and TLR9 signaling in CVID B cells.
METHODS: TLR7-mediated, TLR7/8-mediated, and TLR9-mediated cell proliferation, isotype switch, and immunoglobulin production by control and CVID B cells or isolated naive and memory B cell subsets were examined. We quantitated TNF-alpha, IL-6, and IL-12 production in response to TLR1-9 ligands and measured IFN-alpha production by TLR7-stimulated PBMCs and isolated plasmacytoid dendritic cells (pDCs). IFN-beta mRNA expression by TLR3-stimulated fibroblasts was assessed.
RESULTS: Unlike CD27(+) B cells of controls, TLR7-activated, TLR7/8-activated, or TLR9-activated CVID B cells or isolated CD27(+) B cells did not proliferate, upregulate CD27, or shed surface IgD. TLR-stimulated CVID B cells failed to upregulate activation-induced cytosine deaminase mRNA or produce IgG and IgA. TLR7-stimulated PBMCs and pDCs produced little or no IFN-alpha. Reconstituting IFN-alpha in TLR7-stimulated CVID B-cell cultures facilitated proliferation, CD27 upregulation, and isotype switch. These TLR defects are restricted because CVID PBMCs stimulated with TLR ligands produced normal amounts of TNF-alpha, IL-6, and IL-12; TLR3-mediated expression of IFN-beta by CVID fibroblasts was normal.
CONCLUSION: Defective TLR7 and TLR9 signaling in CVID B cells and pDCs, coupled with deficient IFN-alpha, impairs CVID B cell functions and prevents TLR-mediated augmentation of humoral immunity in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19592080      PMCID: PMC2908501          DOI: 10.1016/j.jaci.2009.05.019

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  56 in total

1.  Quantitative analysis of lymphocyte differentiation and proliferation in vitro using carboxyfluorescein diacetate succinimidyl ester.

Authors:  J Hasbold; A V Gett; J S Rush; E Deenick; D Avery; J Jun; P D Hodgkin
Journal:  Immunol Cell Biol       Date:  1999-12       Impact factor: 5.126

2.  Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling.

Authors:  Misako Matsumoto; Satomi Kikkawa; Masayoshi Kohase; Kensuke Miyake; Tsukasa Seya
Journal:  Biochem Biophys Res Commun       Date:  2002-05-24       Impact factor: 3.575

3.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL.

Authors:  Mikhail B Litinskiy; Bernardetta Nardelli; David M Hilbert; Bing He; Andras Schaffer; Paolo Casali; Andrea Cerutti
Journal:  Nat Immunol       Date:  2002-08-05       Impact factor: 25.606

4.  Immune competence and switched memory B cells in common variable immunodeficiency.

Authors:  Jimmy Ko; Lin Radigan; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2005-07       Impact factor: 3.969

Review 5.  Natural type I interferon-producing cells as a link between innate and adaptive immunity.

Authors:  Norimitsu Kadowaki; Yong-Jun Liu
Journal:  Hum Immunol       Date:  2002-12       Impact factor: 2.850

6.  Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.

Authors:  Sheila J Gibson; Jana M Lindh; Tony R Riter; Raymond M Gleason; Lisa M Rogers; Ashley E Fuller; JoAnn L Oesterich; Keith B Gorden; Xiaohong Qiu; Scott W McKane; Randy J Noelle; Richard L Miller; Ross M Kedl; Patricia Fitzgerald-Bocarsly; Mark A Tomai; John P Vasilakos
Journal:  Cell Immunol       Date:  2002 Jul-Aug       Impact factor: 4.868

7.  Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease.

Authors:  Klaus Warnatz; Axel Denz; Ruth Dräger; Moritz Braun; Christoph Groth; Guido Wolff-Vorbeck; Hermann Eibel; Michael Schlesier; Hans Hartmut Peter
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

8.  IFN-alpha/beta enhances BCR-dependent B cell responses.

Authors:  Déborah Braun; Iris Caramalho; Jocelyne Demengeot
Journal:  Int Immunol       Date:  2002-04       Impact factor: 4.823

9.  Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.

Authors:  Veit Hornung; Simon Rothenfusser; Stefanie Britsch; Anne Krug; Bernd Jahrsdörfer; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

10.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

View more
  40 in total

1.  Defective B-cell response to Toll-like receptor-9 ligands in common variable immunodeficiency.

Authors:  Julie Y Patel; Sapandeep K Singh; David P Huston
Journal:  Curr Allergy Asthma Rep       Date:  2010-09       Impact factor: 4.806

2.  NOD2 polymorphisms in clinical phenotypes of common variable immunodeficiency disorders.

Authors:  K Packwood; E Drewe; E Staples; D Webster; T Witte; J Litzman; W Egner; R Sargur; W Sewell; E Lopez-Granados; S L Seneviratne; R J Powell; B L Ferry; H M Chapel
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

3.  CD19 controls Toll-like receptor 9 responses in human B cells.

Authors:  Henner Morbach; Jean-Nicolas Schickel; Charlotte Cunningham-Rundles; Mary Ellen Conley; Ismail Reisli; Jose Luis Franco; Eric Meffre
Journal:  J Allergy Clin Immunol       Date:  2015-10-21       Impact factor: 10.793

4.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

5.  IgH sequences in common variable immune deficiency reveal altered B cell development and selection.

Authors:  Krishna M Roskin; Noa Simchoni; Yi Liu; Ji-Yeun Lee; Katie Seo; Ramona A Hoh; Tho Pham; Joon H Park; David Furman; Cornelia L Dekker; Mark M Davis; Judith A James; Kari C Nadeau; Charlotte Cunningham-Rundles; Scott D Boyd
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

6.  Common variable immunodeficiency: two mutations are better than one.

Authors:  Antonio La Cava
Journal:  J Clin Invest       Date:  2013-09-24       Impact factor: 14.808

Review 7.  Toll-like receptor signaling in primary immune deficiencies.

Authors:  Paul J Maglione; Noa Simchoni; Charlotte Cunningham-Rundles
Journal:  Ann N Y Acad Sci       Date:  2015-04-30       Impact factor: 5.691

Review 8.  Common variable immune deficiency: Dissection of the variable.

Authors:  Charlotte Cunningham-Rundles
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

9.  Naturally occurring mutation affecting the MyD88-binding site of TNFRSF13B impairs triggering of class switch recombination.

Authors:  Maria B Almejun; Montserrat Cols; Marta Zelazko; Matias Oleastro; Andrea Cerutti; Pablo Oppezzo; Charlotte Cunningham-Rundles; Silvia Danielian
Journal:  Eur J Immunol       Date:  2013-01-18       Impact factor: 5.532

Review 10.  Primary B-cell immunodeficiencies.

Authors:  Tukisa Smith; Charlotte Cunningham-Rundles
Journal:  Hum Immunol       Date:  2018-10-22       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.